Oxford Nanopore Technologies Plc · LSE:ONT
Oxford Nanopore Technologies — JPM 2024
30 slides from Oxford Nanopore Technologies's conference presentation, Jan 9, 2024
Slide 1: JPM 2024
JPM 2024 Gordon Sanghera, CEO 9 January 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Oxford Nanopore Technologies plc (“Oxford Nanopore”) for information purposes only and does not constitute an offer of, or solicitation to purchase or subscribe for, any securities in which such offer or solicitation is unlawful or to any person to w
Slide 3: Oxford Nanopore Technologies (ONT)
Oxford Nanopore Technologies (ONT) Single molecule sensing platform Expanding Customer Base Highly differentiated sensing Scientific Research customers platform: initial application in expanding to now include clinical DNA/RNA sequencing MinION Launched 2015. Today >7,300 customers in >120 countries
Slide 4: Oxford Nanopore financial performance
Oxford Nanopore financial performance ~£169m FY23 preliminary numbers £146.8m £127.0m ~£169m ~75% LSRT revenue Revenue accounted for by consumables £65.5m £52.1m ~39% ~£467m £32.5m Underlying revenue Cash, cash equivalents growth and liquid investments 2018 2019 2020 2021 2022 2023E Oxford Nanopore
Slide 5: Medium to long-term targets
Medium to long-term targets Medium term (FY26) Disruptive innovation Commercial operations Financial Guidance >30% Underlying LSRT revenue growth Sample to answer workflows Expand geographical footprint directly or through channel partners of LSRT revenue Q Line products designed for regulated Key,
Slide 6: DNA is the source code of all living things…
DNA is the source code of all living things… What is it? Is it healthy or Is it harmful? What is in it? diseased? Is it changing? What is How does it vary from Responding? the disease? others? Metagenome Virus Bacteria Mammal Human Crop Mixed species Eg Influenza A Eg E.coli Eg cow 3Gb x 2 Eg wheat
Slide 7: …and is the source code of biological function
…and is the source code of biological function Beyond DNA, Oxford Nanopore is changing the meaning of multiomics Central Dogma of Biology Legacy Multiomics Nanopore Multiomics $$ and complex Genomics: SBS SNV Nanopore DNA SV Microarray Epigenetics native DNA Bisulfite Fragmentomics sequencing Direct
Slide 8: Our Journey
Our Journey Strong technology foundations Powering today’s products…and future ones 10,000 – 100,000 Channels per flow cell 1 Channel 512 Channels 128,400 Channels One platform Axopatch MinION PromethION P48 Flongle Multiomics Voltage Sensing 1 Nanopore channel 512 channels per 2675 channels per Min
Slide 9: Nanopore Sequencing
Nanopore Sequencing 6 key components 01. MOTOR 02. NANOPORE 03. RUN CONDITIONS Nanopore Sequencing (Salt, fuel, software) Highly Differentiated Sensing Technology Three types of flow cells with 100s to 1000s of individual nanopore channels Customers prepare samples with our range of fast and simple
Slide 10: Real time basecalling and analysis
Real time basecalling and analysis Highly accelerated ML/AI algorithms Rapid development of EPI2ME, our cloud with latest software release and local informatics software MinION: Apple M1 max or M2 max Real-time Q20 basecalling of 1 MinION Flow Cell GridION: GV100 Real-time Q20 basecalling of 5 MinIO
Slide 11: Nanopore accuracy today
Nanopore accuracy today Tenured & tenacious R&D group continuously improving performance Complete genomic information from a single run Epigenetic variation 99.6% accuracy 99.3% 99.9% Simplex Duplex In field today SV calling 96.1% accuracy 99.7% Q40+ Variant calling “T2T” Human Consensus Phasing Meg
Slide 12: We can finally uncover all areas of the genome
We can finally uncover all areas of the genome Small variants SNPs and INDELs well characterised by existing technology. E.g. Sickle cell disease and cystic fibrosis Larger, more complex variants Structural variants including Copy Number Variants, Repeats, Expansions only fully visible with the adve
Slide 13: DNA Sequencing has been in a 'Mainframe' moment
DNA Sequencing has been in a ‘Mainframe’ moment Nanopore sequencing technology enables real-time, affordable, accessible and high performance, in small to high throughput formats. © 2024 Oxford Nanopore Technologies plc. Oxford Nanopore Technologies products are not intended for use for health asses
Slide 14: Our fully scaled platform
Our fully scaled platform From small handheld to flexible high-capacity systems all highly affordable through our OpEx Models Personal Sequencers Scale-up Sequencers High Throughput Sequencers MinION PromethION P2 GridION PromethION P2(i) PromethION P24 PromethION P48 2 FC’s & 1 Kits solo 8 FC’s & 2
Slide 15: Our business model
Our business model Seed the market with Expand the market with self-service Take market share with affordable starter packs MinION and P2 Solo user base classic “B2B approach GridION and PromethION More than 80% of orders are P2(i), P24 and P48 are placed without interaction With sequencers from onl
Slide 16: Our customers
Our customers Commercial resources to fit customer types S1 S2 S3 “genomic explorers” “expanding everyday sequencing” “multi-installation customers” Under $25,000 $25,000 – $250,000 >$250,000 © 2024 Oxford Nanopore Technologies plc. Oxford Nanopore Technologies products are not intended for use for
Slide 17: Driving down cost per genome with every step change
Driving down cost per genome with every step change Price per Price per Price per Price per genome** genome** genome** genome** ~$690 ~$345 ~$235 <$200 20,000 Human genome sequencing capacity1 / year 19,968 15,000 14,976 10,000 9,984 9,984 5,000 7.488 4,992 4,992 4,000 3,000 2,000 2,496 832 1,000 62
Slide 18: Highly differentiated sequencing platform
Highly differentiated sequencing platform Richer insights Faster time to result Accessible & affordable Complement rapid sample prep with Fully accessible with starter pack model Sequence Native DNA/ RNA of any length data streaming & no need for batching and competitive price per GB © 2024 Oxford N
Slide 19: Why customers invest in our platform
Why customers invest in our platform Sequencing as an Breaking the boundaries Exciting pipeline of everyday tool of science novel capabilities © 2024 Oxford Nanopore Technologies plc. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate
Slide 20: We are at the beginning of our transformational journey
We are at the beginning of our transformational journey DISCOVERY TRANSLATION TRANSLATION TRANSLATION TRANSLATION SCIENCE TO HUMANS TO PATIENTS INTO PRACTICE TO COMMUNITY Breakthrough Forging new ground in Move to specialist Deploy in Next generation of research clinical research centres hospitals h
Slide 21: Celebrating scientific advances published by the Nanopore Community
Celebrating scientific advances published by the Nanopore Community 2016 2019 2020 2021 2022 2022 Real-time, portable <1-day Community Largest animal 3-hour newborn High school student Ebola outbreak turnaround for advances in genome assembled: sequencing first to sequence surveillance microbial ada
Slide 22: Translated to our core commercial focus areas
Translated to our core commercial focus areas Priority research applications act as foundation for emerging clinical applications Human Cancer Infectious High Throughput WGS at Cancer Research & Viral, Microbial, Infectious Scale from High-N-to-PopGen Immuno-Oncology Applications & Synthetic Genomes
Slide 23: Reflected by the breadth of applications from our customers
Reflected by the breadth of applications from our customers From rapid WGS to liquid biopsy and beyond “Genetic tests just aren’t thought CNV analysis in The ONT platform's deployability Nanopore metagenomics can of as tests that come back neurodevelopmental disorders: and short turnaround time make
Slide 24: Global Life Science Research (LSRT) commercial team has been developed and regionalised
Global Life Science Research (LSRT) commercial team has been developed and regionalised Maximise regional opportunities with coherent, locally adapted strategies 1. Americas Sales | Support | Marketing 2. EMEA & India Sales | Support | Marketing 3. APAC Sales | Support | Marketing Commercial team ha
Slide 25: Substantial and growing market opportunity: DNA/RNA sequencing
Substantial and growing market opportunity: DNA/RNA sequencing $6.2 billion1 in 2022, expected CAGR 2022-25 ~15%1 Substantial opportunity to penetrate, reshape and expand RESEARCH CLINICAL & APPLIED DIAGNOSTIC & APPLIED INDUSTRIAL Biomedical research Clinical research, More regulated Oxford Nanopore
Slide 26: We continue to innovate in LSRT, and lock down in applied
We continue to innovate in LSRT, and lock down in applied From rapid innovation to rapid, applied insights Life Science Research Products Q-Line Applied market and partner products 1 2 3 4 Q Feature frozen product A Locked for specific application Q Software & consumable version A Software & consuma
Slide 27: Sample to answer
Sample to answer TurBOT Benchtop device capable of sample extraction, Fully hands off Flexibility to meet library prep, sequencing, and data analysis nanopore sequencing your needs Extract, prepare, sequence, MinIONTM or PromethIONTM 2 analyse all-in-one Solo on board benchtop device Scalable and in
Slide 28: We draw on a broad universe of potential partners and collaborators
We draw on a broad universe of potential partners and collaborators Oncology Announced Partnerships in Clinical & Applied Industrial Nanopore Human Genetics Research Community Infectious Disease Vet & Ag Biopharma QC Large Companies Food & Env © 2024 2023 Oxford Nanopore Technologies plc Oxford Nano
Slide 29: Key medium-term revenue drivers
Key medium-term revenue drivers Expanding, underpenetrated market opportunity coupled with unique features and benefits of Oxford Nanopore’s technology underpin growth >30% underlying CC growth p.a. Robust innovation pipeline with frequent platform upgrades and product launches Increased penetration
Slide 30: END
END (:NANOPORE